Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
31°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
125.78
+0.55 (+0.44%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
January 26, 2024
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
Via
Benzinga
Topics
Government
Exposures
Political
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
January 25, 2024
LAVA Therapeutics collaborates with Merck on a clinical trial for anti-PD-1 therapy Keytruda in metastatic castration-resistant prostate cancer.
Via
Benzinga
3 S&P 500 Stocks With 127% to 170% Upside in 2024, According to Select Wall Street Analysts
January 25, 2024
Wall Street's benchmark index is comprised of 500 companies, three of which could deliver triple-digit upside in the new year.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today?
January 24, 2024
Evaxion Biotech revolutionizes cancer vaccine development, targeting AI-identified ERVs. Preclinical activities underway; Proof-of-Concept data expected by 2H 2024.
Via
Benzinga
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
January 24, 2024
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population.
Via
InvestorPlace
Smart Money Is Betting Big In MRK Options
January 10, 2024
Via
Benzinga
Peering Into Merck & Co's Recent Short Interest
January 10, 2024
Via
Benzinga
Demystifying Merck & Co: Insights From 9 Analyst Reviews
January 09, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 24, 2024
It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning.
Via
InvestorPlace
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
January 23, 2024
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.
Via
The Motley Fool
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test
January 22, 2024
The company had hoped Trodelvy would extend overall survival for patients with a form of lung cancer.
Via
Investor's Business Daily
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
January 22, 2024
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns.
Via
InvestorPlace
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
January 20, 2024
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech...
Via
Talk Markets
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
January 19, 2024
2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
January 19, 2024
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups.
Via
Benzinga
Exposures
Product Safety
Why Is Cancer Focused Adagene Stock Plummeting Today?
January 17, 2024
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in...
Via
Benzinga
The 3 Best Dividend Growth Stocks to Buy in January 2024
January 17, 2024
These are the best dividend growth stocks to buy as they represent companies with healthy free cash flow upside visibility.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
January 16, 2024
FDA approves Merck's Keytruda for advanced cervical cancer. Keytruda plus chemoradiotherapy shows a 41% improvement in progression-free survival.
Via
Benzinga
Exposures
Product Safety
7 Healthcare Stocks Taking Medicine to the Next Level
January 14, 2024
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider.
Via
InvestorPlace
These 9 Stocks Are Running To Start 2024
January 14, 2024
The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
The 3 Best Blue-Chip Stocks to Buy in January 2024
January 10, 2024
With a history of consistent shareholder returns, the best blue-chip stocks will reward patient investors in 2024.
Via
InvestorPlace
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...
Via
Benzinga
Exposures
COVID-19
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
January 08, 2024
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Via
Benzinga
Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics
January 08, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.